The combination of dabrafenib and trametinib has already shown the activity in BRAF-mutated melanoma, thyroid cancer, as well as lung cancer, and therefore has been approved by the US FDA for the treatment of these cancers. In NCI-MATCH trial (Arm H), the effects of this regimen in other BRAF V600 mutated cancer types were evaluated. Of the total of 33 enrolled patients across 17 tumor types (including lung cancer), 16 (48.5%) had received three or more prior lines of systemic treatments. The results showed that the ORR was 33.3% (90% CI 19.9-49.1%) and the median DoR was 12 months. At the time of data cutoff (April 2019), ten patients remained on active therapy. Interestingly, patients with gynecological cancer or cholangiocarcinoma had better responses than those with other cancer types. Above results suggested that dabrafenib plus trametinib is a potential therapeutic strategy for patients who carried a BRAF V600 mutated tumor, especially for those with gynecological cancer and cholangiocarcinoma.
J Clin Oncol 37, 2019 (suppl; abstr 3002)